NDAC meetings
This article was originally published in The Tan Sheet
Executive Summary
Nonprescription drugs advisory panel will meet jointly with the Dermatologic & Ophthalmic committee to "discuss what should be the necessary and sufficient safety database in order to evaluate the [Rx-to-OTC] switch of topical corticosteroids, especially the database to evaluate the potential for hypothalamic, pituitary, adrenal (HPA) and growth suppression and other systemic and local adverse reactions." The committee will convene at the Washington D.C. Hilton on March 24 from 8 am-5:30 pm, with the hour between 1 pm-2 pm reserved for public comment. NDAC will hold a separate meeting on March 23 to evaluate "microbiologic surrogate endpoints used to demonstrate the effectiveness of antiseptic products used in health care settings"...
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.